Manning & Napier Target 2055 Series Class I
MTZIX
NASDAQ- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Manning & Napier Target 2055 Series Class I (MTZIX) is a target date collective investment trust (CIT) fund that seeks long-term capital growth and risk management for investors planning retirement around 2055 by investing primarily in underlying Manning & Napier Pro-Mix® CIT Funds according to a predetermined glide path. The fund maintains an aggressive, growth-oriented portfolio with current equity exposure ranging from 70%-95%, diversified across domestic and foreign stocks; fixed income holdings; and minimal cash equivalents, gradually shifting to more conservative allocations with stock exposure reducing to 20%-60% near the target date and 13%-47% five years beyond. Its core offerings include Class I units available exclusively within qualified employee benefit plans, with a net expense ratio of 0.69% that incorporates acquired fund fees and reflects contractual fee limitations; as of May 31, 2025, the asset allocation comprised 86.44% equity, 12.08% fixed income, and 1.48% cash equivalents, benchmarked primarily against the Manning & Napier Pro-Mix Maximum Term CIT Fund. Manning & Napier Target 2055 Series Class I, with inception on October 11, 2012 (historical data from January 1, 2000), operates globally through its underlying funds' investments in U.S. and international markets, managed by Manning & Napier Advisors, LLC, headquartered in Fairport (Rochester area), New York. In recent developments, the fund continued its glide path adjustments amid market conditions, delivering year-to-date performance of 2.32% and 10-year annualized returns of 8.93% as of May 31, 2025; meanwhile, its sponsor underwent a significant strategic shift with the October 2022 completion of a take-private acquisition by Callodine Group LLC, enabling enhanced client-focused operations without public market pressures, followed by active portfolio maneuvers such as initiating a major position in Albemarle Corp in third-quarter 2025.